2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1894 Comparative efficacy and two-year survival outcomes of Pola-R-CHP versus R-CHOP: A comprehensive inverse probability of treatment weighting (IPTW) analysis

Shenmiao Yang, PhD, Yu Zhao, MD2, Jianxia He3, Kaili Zhong, MD4, Haisheng Liu5, Yan-ying Wang6, Huizheng Bao7, Ming Gong8, Ou Bai, MD9, Renna Wu10
1 Peking University People‘s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Treatment of Hematologic Disease, Beijing, China
2 Chinese PLA General Hospital, Beijing, Beijing, China
3 Shanxi Provincial People's Hospital, Shanxi, China
4 Beijing Shijitan Hospital, Beijing, China
5 The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital, Shijiazhuang, China
6 Beijing Tsinghua Changgeng Hospital, Beijing, China
7 Jilin Cancer Hospital, Changchun, China
8 China-Japan Friendship Hospital, Beijing, China
9 The First Bethune Hospital of Jilin University, Changchun, China
10 Affiliated Hospital of Chifeng University, Chifeng, China

Background: Although the pivotal POLARIX trial established that Pola-R-CHP significantly improves progression-free survival (PFS) over R-CHOP in untreated intermediate/high-risk DLBCL, real-world long-term follow-up evidence remains limited. This study evaluated initial tumor response rates and long-term survival outcomes comparing Pola-R-CHP with R-CHOP in a real-world clinical cohort.

Methods: This is a multi-center, retrospective, cohort study. Patients aged ≥18 years with untreated DLBCL treated with either R-CHOP (Jan 2017–May 2025) or Pola-R-CHP (Apr 2023–Dec 2025) were analyzed. To control the baseline selection bias, Inverse Probability of Treatment Weighting (IPTW) was applied using propensity scores derived from a multivariable logistic regression model incorporating the following eight covariates: Age, Gender, IPI, Disease Stage, Bulky status, Extranodal (EN) involvement, ECOG performance status and Hans classification. Baseline balance was assessed using Standardized Mean Differences (SMD < 0.10 indicating optimal balance). Primary endpoints were Best Overall Response Rate (ORR) and Best Complete Response Rate (CRR); secondary endpoints included PFS and Overall Survival (OS). Odds ratios (ORs) for CRR and ORR were estimated using logistic regression, whereas hazard ratios (HRs) for PFS and OS were estimated using Cox proportional hazards models.

Results: The unweighted cohort included 106 patients receiving R-CHOP and 220 receiving Pola-R-CHP. Initially the two arms were well-balanced regarding age (mean 61.2 vs. 61.8 years, p = 0.723; SMD = 0.041), gender (male: 52.8% vs. 50.5%, p = 0.777; SMD = 0.048), and Hans classification (ABC subtype: 63.2% vs. 61.4%, p = 0.842; SMD = 0.038). However, notable baseline imbalances were present in disease stage (Stage III–IV: 88.7% vs. 82.3%, p = 0.184; SMD = 0.183), high IPI score (3–5: 58.5% vs. 68.2%; SMD = 0.202), EN involvement (>1 EN site: 60.5% vs. 32.1%, p < 0.001; SMD = 0.594), ECOG status (p = 0.017, SMD = 0.299), and bulky disease >7.5 cm (19.8% vs. 27.7%; SMD = 0.187). After IPTW, the effective sample sizes for R-CHOP and Pola-R-CHP were 81.5 and 204.8, respectively. All evaluated covariates achieved excellent balance with SMDs < 0.10 (e.g., EN status SMD = 0.026; ECOG status SMD = 0.019; IPI SMD = 0.067).  

Tumor response rates were comparable between groups in the weighted cohort. Weighted CRR was 80.4% (95% CI: 69.2–88.2) for R-CHOP vs. 76.6% (95% CI: 70.3–81.9) for Pola-R-CHP (Weighted OR: 0.80, 95% CI: 0.41–1.57, p = 0.516). Similarly, Weighted ORR was 93.2% (95% CI: 84.5–97.2) for R-CHOP vs. 93.3% (95% CI: 89.0–96.0) for Pola-R-CHP (Weighted OR: 1.02, 95% CI: 0.35–2.95, p = 0.978). There was no statistically significant difference between the two groups.

After IPTW, the median overall follow-up was 28.4 months (95% CI: 24.6–40.0) in the R-CHOP group and 18.7 months (95% CI: 16.8–21.0) in the Pola-R-CHP group.

In the IPTW-adjusted analysis, Pola-R-CHP significantly extended Progression-Free Survival (PFS). The 12-months weighted PFS rate was higher in the Pola-R-CHP arm at 81.9% (95% CI: 76.7–87.5) compared to 75.9% (95% CI: 67.1–85.9) in the R-CHOP arm. This superiority was maintained at 24 months, with a weighted PFS of 79.6% (95% CI: 73.9–85.8) for Pola-R-CHP vs. 66.4% (95% CI: 56.6–77.8) for R-CHOP, representing a significant 44% reduction in the hazard of disease progression or death (Weighted HR: 0.56, 95% CI: 0.35–0.89, p = 0.014). Furthermore, Overall Survival was significantly enhanced: the 12-month weighted OS rate was 96.0% (95% CI: 93.4–98.7) for Pola-R-CHP versus 88.8% (95% CI: 81.6–96.5) for R-CHOP, and the 24-month weighted OS rate remained markedly higher with Pola-R-CHP (95.4% [95% CI: 92.6–98.3] vs. 82.4% [95% CI: 73.6–92.2]), achieving a 74% reduction in mortality risk (Weighted HR: 0.26, 95% CI: 0.11–0.59, p = 0.001)

Conclusion: This comprehensive IPTW-adjusted clinical analysis demonstrates that while the Pola-R-CHP and R-CHOP regimens elicit comparable, high rates of overall response and complete responses, the Pola-R-CHP regimen confers a substantial and highly significant long-term survival advantage. Consequently, Pola-R-CHP represents a remarkably enhanced therapeutic regimen in 1L DLBCL, offering enduring disease control and transforming long-term prognosis.

Shenmiao Yang, PhD: No relevant conflicts of interest to declare.